Department of Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University, No. 277, Yanta West Road, Xi'an, 710061, Shanxi, China.
Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Med Oncol. 2019 Sep 6;36(10):84. doi: 10.1007/s12032-019-1307-8.
As the prognosis of colorectal cancer (CRC) does not always coincide with the pathology and/or surgical findings, a reliable noninvasive prediction tool for the prognosis of CRC is needed. Patients admitted for initial treatment of CRC between January 1, 2015 and December 31, 2015 were retrieved and reviewed. Records of circulating CD16+ CD56+ natural killer (NK) cells were analyzed before and after the initial chemotherapy of FOLFOX plan. Patients were followed up until June 30, 2019. One hundred and twenty-four cases after the FOLFOX chemotherapy were enrolled into this study. There were no significant differences in gender, age, or number of metastasis cases between the survival group and the nonsurvival group (p > 0.05), but significant differences in pre-chemotherapy, post-chemotherapy, and the differences between pre- and post-chemotherapy circulating CD16+ CD56+ NK cells between the survival group and the nonsurvival group (p < 0.01, p < 0.01, and p < 0.05, respectively) were observed. For the prediction of survival and nonsurvival CRC cases, the Areas Under the Curve were 0.626 and 0.759 in the Receiver-Operating Characteristic curves for the pre- and post-chemotherapy circulating CD16+ CD56+NK cells, respectively. Using an optimal cutoff value of 11.8% in post-chemotherapy circulating CD16+CD56+NK cells to differentiate survival and nonsurvival cases, the odds ratio was 0.12 (0.05, 0.27), p < 0.001. The percentages of both pre-chemotherapy and post-chemotherapy circulating CD16+CD56+NK cells were negatively correlated with the prognosis of CRC. The percentage of post-chemotherapy circulating CD16+CD56+NK cells was able to effectively predict the prognosis of CRC cases.
由于结直肠癌（CRC）的预后并不总是与病理和/或手术结果相符，因此需要一种可靠的非侵入性预测 CRC 预后的工具。检索并回顾了 2015 年 1 月 1 日至 2015 年 12 月 31 日期间因初始 CRC 治疗而入院的患者。分析了接受 FOLFOX 方案初始化疗前后循环 CD16+CD56+自然杀伤（NK）细胞的记录。患者随访至 2019 年 6 月 30 日。本研究共纳入 124 例接受 FOLFOX 化疗后的病例。生存组和非生存组在性别、年龄或转移病例数方面无显著差异（p>0.05），但在化疗前、化疗后以及化疗前后循环 CD16+CD56+NK 细胞的差异方面存在显著差异（p<0.01、p<0.01 和 p<0.05，分别）。对于预测生存和非生存 CRC 病例，化疗前后循环 CD16+CD56+NK 细胞的受试者工作特征曲线下面积分别为 0.626 和 0.759。使用化疗后循环 CD16+CD56+NK 细胞的最佳截断值 11.8%来区分生存和非生存病例，优势比为 0.12（0.05，0.27），p<0.001。化疗前和化疗后循环 CD16+CD56+NK 细胞的百分比均与 CRC 的预后呈负相关。化疗后循环 CD16+CD56+NK 细胞的百分比能够有效预测 CRC 病例的预后。
